Hints and tips:
...H1, Mastercard Q2, Merck & Co Q2, Nestlé H1, Nissan Motor Q1, Northrop Grumman Q2, OMV Q2, Orange H1, Panasonic Q1, Pfizer Q2, Relx H1, Rentokil Initial H1, Repsol Q2, Royal Dutch Shell Q2, Samsung Q2, Sanofi-Aventis...
...This exhibition at the V&A invites us into the opulent world of master goldsmith Carl Fabergé and his London clientele....
...It has been a year that most US distressed hedge funds would love to forget....
...Causeway Capital Management LLC, the LA hedge fund, has declared 4.88 per cent of Micro Focus....
...(v) Restructuring continues. Of course it does. But what about that Tesla, eh?...
...France's pharma giant Sanofi and Celgene, the US biotech group, unveiled two large acquisitions on Monday worth more than $20bn....
...Mr Miels started his pharmaceuticals career at AstraZeneca in 1995, leaving in 2000 for Sanofi-Aventis before joining Switzerland’s Roche in 2006, where he ran the company’s Asia business....
...For fun, here was the calculation Leslie and I did that got us to a $4.2bn transaction value, which eventually matched the revised value cited by Tibco (by dumb luck, or not)....
...The changes are due to come into effect next year in the US and in about 18 months’ time in Europe....
..., the French drugmaker, against a hostile takeover by rival Sanofi....
...Bankruptcy We discussed this at some length on Monday because it reminded us of Texas Competitive Electric Holdings Company LLC (TCEH) in 2011....
...He also has served on the board of Genzyme, the biotech company sold to Sanofi-Aventis this year for more than $20bn....
...In a research note on Monday, Cowen argued that a number of the large pharmaceutical groups, led by Eli Lilly, Sanofi-Aventis and Pfizer, would be worth more if they divested separable business units, which...
...Sanofi-Aventis has continued aggressively to acquire others, including ultimately winning support for the takeover of US group Genzyme after raising its bid above $20bn....
...Stute, currently co-head of North American M&A, will become head of the North America healthcare group, while Robbie Huffines, who advised Merck on its acquisition of Schering Plough and is working with Sanofi-Aventis...
...Diabetes medications still make up about 17 per cent of Lilly’s $22bn revenues, but in recent years it has lost ground to rivals such as Merck and Sanofi-Aventis....
...“Such a deal would likely be accretive for Sanofi on a core basis, although the value impact is less certain,” cautioned Morgan Stanley in a research note in mid August....
...Sanofi-Aventis stepped up its pursuit of Genzyme on Sunday, outlining publicly its interest in a takeover deal as it inched closer to making a hostile offer for the US biotech company....
...In a research note, Morgan Stanley, which maintained its rating of Sanofi-Aventis as “equal weight” concluded: “The prospects of an acquisition appear increasingly plausible, in our view, and could well...
...US-listed shares in Sanofi-Aventis fell 1.6 per cent to $33.58. As the earnings season drew to a close Tyson Foods was one of the last companies to report....
...Chris Viehbacher, head of Sanofi-Aventis, the French drugmaker, rejects the suggestion that payments need cause insuperable problems....
...US-listed shares in Sanofi-Aventis lost 1.2 per cent to $33.60, while US-listed shares in Takeda Pharmaceutical slid 0.8 per cent to $23.55....
...France’s Sanofi-Aventis opted to partner Nichi-Iko last year. Japan’s Daiichi Sankyo, Mitsubishi Tanabe Pharma and Fujifilm have also said they will enter the fray....
...High factory automation has helped contain V-Zug’s costs, including a smart new computerised logistics centre opened this year. “Productivity is a key success factor for us,” Mr Buhofer says....
...Strong flu vaccine sales and cost savings helped Sanofi-Aventis maintain guidance for 2010 at 2-5 per cent growth in earnings per share in spite of patent expiries and short-term pressure from US healthcare...
International Edition